Noisette
Established Member
- Reaction score
- 1,341
Ladies and gentlemen,
Doctor Cotsarelis is an owner of some New patents related to Hair Loss.
I've already posted here, on an another thread, 2 of them, but I found 3 another ones.
Here we go
-------------------------------------------------------------------------------------------------------------------------------------------------
1. Minoxidil for generating new hair follicles and treating baldness
Publication date: 2 Dec 2015
Filing date: 28 Mar 2006
Source: www.google.com/patents/EP2949328A1?cl=en&hair loss=fr
ABSTRACT
Use of minoxidil for the preparation of a pharmaceutical composition for treating a subject to generate a hair follicle and/or to increase the size of a hair follicle in a scalp, eyebrow or scarred region. The treating comprises disrupting an epidermis of the scalp, eyebrow or scarred region, and contacting it with the pharmaceutical composition. The subject may have androgenetic alopecia (Androgenetic Alopecia).
A non-therapeutic method for generating a hair follicle and/or increasing the size of a hair follicle in a scalp, eyebrow or scarred region of a subject. The method comprises disrupting an epidermis of the scalp, eyebrow or scarred region, and contacting it with minoxidil. The subject may have male pattern baldness or female pattern baldness.
(...) Follicular neogenesis is defined as the generation of new hair follicles (HF) after birth. Humans are born with a full complement of HF, which can change in size and growth characteristics as in early baldness or can ultimately degenerate and disappear as in late stages of baldness or in permanent scarring (cicatricial) alopecias. Therefore, the generation of new HF is desirable in the treatment of common baldness as well as less common hair loss conditions, such as discoid lupus erythematosis, congenital hypotrichosis, lichen planopilaris and other scarring alopecias.
-------------------------------------------------------------------------------------------------------------------------------------------------
2. Shh signaling pathway stimulating agents for treating hair loss (FGF9 !! )
Publication date: 22 Mar 2017
Filing date: 11 Nov 2009
Source: www.google.com/patents/EP3144034A1?cl=en&hair loss=fr
ABSTRACT:
A composition for use in treating hair loss in a subject, wherein the composition comprises an agent that stimulates one or more members of the SHH signaling pathway, and a non-therapeutic method for treating hair loss in a subject, the method comprising administering a composition comprising an agent that stimulates one or more members of the SHH signaling pathway to the subject. The agent may be a glioma-associated oncogene homolog 1 (GLI1) polypeptide, a glioma-associated oncogene homolog 2 (GLI2) polypeptide, a biologically active fragment thereof, or a homolog thereof.
3. Methods and compositions for inhibiting or reducing hair loss (PGD2 !)
Publication date: 7 Jun 2017
Filing date: 15 Jun 2007
Source: www.google.com/patents/EP3175856A1?cl=en&hair loss=fr
ABSTRACT
A non-therapeutic method of treating baldness in the scalp of a subject, the method comprising administering a prostaglandin D2 receptor (DP receptor) antagonist to the subject. The antagonist may be a prostaglandin D2 receptor 2 (DP2 receptor) antagonist.
4. Topical Aza-dC treatment on wound healing enhanced hair follicle regeneration.
Aza-dC treatment at all doses tested greatly enhanced hair follicle (HF) neogenesis
Publication date: 27 juil. 2017
Filing date: 21 juil. 2015
Source: www.google.com/patents/US20170209475?hair loss=fr&cl=en
TITLE : 5-aza-2'- deoxycytidine and methods of use thereof for promoting wound healing and regeneration
FIG. 4. Topical Aza-dC treatment enhanced hair follicle regeneration in healed wounds. (A) 10 μL of Aza-dC (dissolved in DMSO) was applied topically to the wound site, once a day, for 2 consecutive days at the time of scab detachment (SD0 & SD1). Aza-dC treatment at all doses tested greatly enhanced hair follicle (HF) neogenesis compared to the vehicle control, with the strongest enhancement seen with the highest tested dose (10 μg). (A) 10 μL of Aza-dC (dissolved in DMSO) was applied topically to the wound site, once a day, for 5 consecutive days at the time of scab detachment (SD0 to SD1). While the two lower doses (1 & 5 μg) showed little effect on the regeneration, the highest dose (10 μg) still enhanced hair follicle regeneration.
Edit: adding the last patent in the first post too
Doctor Cotsarelis is an owner of some New patents related to Hair Loss.
I've already posted here, on an another thread, 2 of them, but I found 3 another ones.
Here we go
-------------------------------------------------------------------------------------------------------------------------------------------------
1. Minoxidil for generating new hair follicles and treating baldness
Publication date: 2 Dec 2015
Filing date: 28 Mar 2006
Source: www.google.com/patents/EP2949328A1?cl=en&hair loss=fr
ABSTRACT
Use of minoxidil for the preparation of a pharmaceutical composition for treating a subject to generate a hair follicle and/or to increase the size of a hair follicle in a scalp, eyebrow or scarred region. The treating comprises disrupting an epidermis of the scalp, eyebrow or scarred region, and contacting it with the pharmaceutical composition. The subject may have androgenetic alopecia (Androgenetic Alopecia).
A non-therapeutic method for generating a hair follicle and/or increasing the size of a hair follicle in a scalp, eyebrow or scarred region of a subject. The method comprises disrupting an epidermis of the scalp, eyebrow or scarred region, and contacting it with minoxidil. The subject may have male pattern baldness or female pattern baldness.
(...) Follicular neogenesis is defined as the generation of new hair follicles (HF) after birth. Humans are born with a full complement of HF, which can change in size and growth characteristics as in early baldness or can ultimately degenerate and disappear as in late stages of baldness or in permanent scarring (cicatricial) alopecias. Therefore, the generation of new HF is desirable in the treatment of common baldness as well as less common hair loss conditions, such as discoid lupus erythematosis, congenital hypotrichosis, lichen planopilaris and other scarring alopecias.
-------------------------------------------------------------------------------------------------------------------------------------------------
2. Shh signaling pathway stimulating agents for treating hair loss (FGF9 !! )
Publication date: 22 Mar 2017
Filing date: 11 Nov 2009
Source: www.google.com/patents/EP3144034A1?cl=en&hair loss=fr
ABSTRACT:
A composition for use in treating hair loss in a subject, wherein the composition comprises an agent that stimulates one or more members of the SHH signaling pathway, and a non-therapeutic method for treating hair loss in a subject, the method comprising administering a composition comprising an agent that stimulates one or more members of the SHH signaling pathway to the subject. The agent may be a glioma-associated oncogene homolog 1 (GLI1) polypeptide, a glioma-associated oncogene homolog 2 (GLI2) polypeptide, a biologically active fragment thereof, or a homolog thereof.
- The invention relates to pharmaceutical compositions and methods for treating hair loss and regenerating hair follicles. Specifically, the invention relates to fibroblast growth factor-9 polypeptides and administering a fibroblast growth factor-9 polypeptide for treating hair loss or regenerating hair follicles.
- [0028]
The present invention provides methods of treating hair loss, treating, inhibiting, or suppressing a degenerative skin disorder, and treating androgenetic alopecia (Androgenetic Alopecia) in a subject and generating new hair follicles (HF) and increasing the size of existing HF, comprising epidermal disruption or administration of wnt, and administration of a fibroblast growth factor-9 polypeptide or another compound that upregulates sonic hedgehog gene signaling.
FGF9- [0059]
In one embodiment, the methods of the present invention comprise the step of administering a composition comprising a fibroblast growth factor-9 polypeptide, alone or in composition with one or more additional compounds. In one embodiment, FGF9 refers to Fgf-9, FGF-9, Fibroblast growth factor 9, GAF, glia activating factor, Glia-activating factor precursor, or HBGF-9. In one embodiment, the FGF9 protein of the methods of the present invention has the sequence: - administration of recombinant human FGF9 increased levels of sonic hedgehog (SHH) gene expression
3. Methods and compositions for inhibiting or reducing hair loss (PGD2 !)
Publication date: 7 Jun 2017
Filing date: 15 Jun 2007
Source: www.google.com/patents/EP3175856A1?cl=en&hair loss=fr
ABSTRACT
A non-therapeutic method of treating baldness in the scalp of a subject, the method comprising administering a prostaglandin D2 receptor (DP receptor) antagonist to the subject. The antagonist may be a prostaglandin D2 receptor 2 (DP2 receptor) antagonist.
EXAMPLE 7: HAIRED SCALP CONTAINS A POPULATION OF CD200 HIGH ALPHA-6 INTEGRIN HIGH CELLS THAT ARE LACKING IN BALD SCALP- [0500]
Haired and bald scalp samples from 5 Androgenetic Alopecia patients were subjected to staining and FACS for alpha-6 integrin and CD200. In each case, haired and bald samples from the same patient were compared. A population of alpha-6 integrinhigh CD200high cells was found to be present in the haired but not bald samples (Figure 9). These findings demonstrate the existence of a stem cell population that can be transplanted to generate new HF and treat baldness. Further, these findings demonstrate that administration of CD200 and analogues thereof can be used to treat baldness.
4. Topical Aza-dC treatment on wound healing enhanced hair follicle regeneration.
Aza-dC treatment at all doses tested greatly enhanced hair follicle (HF) neogenesis
Publication date: 27 juil. 2017
Filing date: 21 juil. 2015
Source: www.google.com/patents/US20170209475?hair loss=fr&cl=en
TITLE : 5-aza-2'- deoxycytidine and methods of use thereof for promoting wound healing and regeneration
FIG. 4. Topical Aza-dC treatment enhanced hair follicle regeneration in healed wounds. (A) 10 μL of Aza-dC (dissolved in DMSO) was applied topically to the wound site, once a day, for 2 consecutive days at the time of scab detachment (SD0 & SD1). Aza-dC treatment at all doses tested greatly enhanced hair follicle (HF) neogenesis compared to the vehicle control, with the strongest enhancement seen with the highest tested dose (10 μg). (A) 10 μL of Aza-dC (dissolved in DMSO) was applied topically to the wound site, once a day, for 5 consecutive days at the time of scab detachment (SD0 to SD1). While the two lower doses (1 & 5 μg) showed little effect on the regeneration, the highest dose (10 μg) still enhanced hair follicle regeneration.
- Early Topical Treatment of DNA Methyl Transferase Inhibitor, Aza-Deoxycytidine (Aza-dC), to the Healing Wound Enhanced Regeneration After Healing
- [0113]
To further reduce the toxicity of Aza-dC treatment, the inhibitor was applied locally to the wound sites. Unlike systemic treatment, topical application of Aza-dC exhibited little inhibitory effect on wound-induced hair follicle regeneration. When applied to the wound site immediately following scab detachment for 2 days only, Aza-dC greatly enhanced hair follicle regeneration in healed wounds (from 3 to 8 fold) in a dose-dependent manner. (FIG. 4). Therefore, up-regulation of certain genes, via inhibition of DNA methylation, at the times when hair follicles begin to form plays a critical role in the hair follicle regeneration. This stimulatory effect on regeneration was diminished when the topical treatment was extended to 5 days (from SD0 to SD4), suggesting that the expression levels of some of these genes need to be temporally controlled to support hair follicle formation
Edit: adding the last patent in the first post too
Last edited:
